Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P

• Published in: The Journal of infectious diseases Vol. 226; no. 9; pp. 1562 - 1567
• Main Authors: Kuo, Tsun-Yung, Lien, Chia En, Lin, Yi-Jiun, Lin, Meei-Yun, Wu, Chung-Chin, Tang, Wei-Hsuan, Campbell, John D, Traquina, Paula, Chuang, Ya-Shan, Liu, Luke Tzu-Chi, Cheng, Jinyi, Chen, Charles
• Format: Journal Article
• Language: English
• Published: United States 01.11.2022
• Subjects: Adjuvants, Immunologic; Animals; Antibodies, Neutralizing; Antibodies, Viral; COVID-19 - prevention & control; COVID-19 Vaccines - immunology; Cricetinae; SARS-CoV-2; Spike Glycoprotein, Coronavirus - immunology; COVID-19 vaccine; SARS-CoV-2 vaccine; variant of concern; subunit vaccine; hamster challenge study; MVC-COV1901
• ISSN: 0022-1899; 1537-6613; 1537-6613
• DOI: 10.1093/infdis/jiac153

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern negatively impact the effectiveness of vaccines. In this study, we challenge hamsters with the delta variant after 2- or 3-dose inoculations with SARS-CoV-2 vaccines constructed from stabilized prefusion spike proteins (S-2P) of Wuhan (W) and beta (B) variants. Compared to 3 doses of W S-2P, 2 doses of W S-2P followed by a third dose of B S-2P induced the highest neutralizing antibody titer against live SARS-CoV-2 virus and enhanced neutralization of omicron variant pseudovirus. Reduced lung live virus titer and pathology suggested that all vaccination regimens protect hamsters from SARS-CoV-2 delta variant challenge.